## Hennessey Jp Jr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8259309/publications.pdf

Version: 2024-02-01

331670 361022 2,068 37 21 35 h-index citations g-index papers 41 41 41 1660 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Information content in the circular dichroism of proteins. Biochemistry, 1981, 20, 1085-1094.	2.5	619
2	NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine, 2012, 30, 7594-7600.	3.8	177
3	A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis—A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2018, 66, 1928-1936.	5.8	134
4	Experimental errors and their effect on analyzing circular dichroism spectra of proteins. Analytical Biochemistry, 1982, 125, 177-188.	2.4	119
5	Development and Validation of an NMR-Based Identity Assay for Bacterial Polysaccharides. Analytical Biochemistry, 2000, 279, 226-240.	2.4	87
6	NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine, 2013, 31, 5549-5556.	3.8	79
7	Carbohydrate composition analysis of bacterial polysaccharides: Optimized acid hydrolysis conditions for HPAEC-PAD analysis. Analytical Biochemistry, 1992, 201, 343-349.	2.4	72
8	Evaluation of Accuracy and Precision of Adenovirus Absorptivity at 260 nm under Conditions of Complete DNA Disruption. Virology, 2002, 295, 284-288.	2.4	71
9	Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Vaccine, 1999, 17, 1169-1178.	3.8	63
10	Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5555-63.	7.1	61
11	Nonredundant Roles of Interleukin-17A (IL-17A) and IL-22 in Murine Host Defense against Cutaneous and Hematogenous Infection Due to Methicillin-Resistant Staphylococcus aureus. Infection and Immunity, 2015, 83, 4427-4437.	2.2	58
12	Molecular size analysis of capsular polysaccharide preparations from Streptococcus pneumoniae. Carbohydrate Research, 1993, 243, 115-130.	2.3	48
13	Conformational transitions of calmodulin as studied by vacuum-UV CD. Biopolymers, 1987, 26, 561-571.	2.4	44
14	Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq®). Journal of Virological Methods, 2006, 131, 193-201.	2.1	43
15	Characterization and quantification of C-polysaccharide in Streptococcus pneumoniae capsular polysaccharide preparations. Analytical Biochemistry, 2005, 336, 262-272.	2.4	40
16	An optimized procedure for sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of hydrophobic peptides from an integral membrane protein. Analytical Biochemistry, 1989, 176, 284-289.	2.4	37
17	Quantitative nuclear magnetic resonance analysis and characterization of the derivatized Haemophilus influenzae type b polysaccharide intermediate for PedvaxHIB. Analytical Biochemistry, 2005, 337, 235-245.	2.4	36
18	Pressure inactivation of tetrameric lactate dehydrogenase homologues of confamilial deep-living fishes. Journal of Comparative Physiology B: Biochemical, Systemic, and Environmental Physiology, 1985, 155, 647-652.	1.5	27

#	Article	IF	CITATIONS
19	Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis. Frontiers in Immunology, 2018, 9, 1349.	4.8	27
20	Protein chemistry of the Neurospora crassa plasma membrane H+-ATPase. Analytical Biochemistry, 1988, 173, 251-264.	2.4	26
21	Subunit interactions of transcarboxylase as studied by circular dichroism. Biochemistry, 1982, 21, 642-646.	2.5	24
22	Evaluation of a microcarrier process for large-scale cultivation of attenuated hepatitis A. Cytotechnology, 1992, 9, 173-187.	1.6	24
23	Pressure-adaptive differences in proteolytic inactivation of M4-lactate dehydrogenase homologues from marine fishes. The Journal of Experimental Zoology, 1987, 241, 9-15.	1.4	23
24	Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus. Frontiers in Immunology, 2014, 5, 463.	4.8	21
25	Alignment of absolute and relative molecular size specifications for a polyvalent pneumococcal polysaccharide vaccine (PNEUMOVAX®23). Biologicals, 2005, 33, 49-58.	1.4	17
26	Configuration of piperitone from oil of Mentha piperita. Phytochemistry, 1983, 22, 2227-2230.	2.9	16
27	A Robust Approach for the Quantitation of Viral Concentration in an Adenoviral Vector-Based Human Immunodeficiency Virus Vaccine by Real-Time Quantitative Polymerase Chain Reaction. Human Gene Therapy, 2006, 17, 728-740.	2.7	11
28	Molecular Size Analysis of <i> Haemophilus Influenzae </i> Type B Capsular Polysaccharide. Journal of Liquid Chromatography and Related Technologies, 1993, 16, 1715-1729.	1.0	10
29	Lessons Learned and Future Challenges in the Design and Manufacture of Glycoconjugate Vaccines. ACS Symposium Series, 2018, , 323-385.	0.5	10
30	Innovative Approaches to Improve Anti-Infective Vaccine Efficacy. Annual Review of Pharmacology and Toxicology, 2017, 57, 189-222.	9.4	9
31	Immunogenicity and safety of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis conjugate vaccine in 7.5 μg liquid formulation: a comparison of three lots with the 15.0 μg lyophilized formulation. Vaccine, 1997, 15, 775-781.	3.8	7
32	Strategy for streamlined release identity testing of chromatography media. Analyst, The, 2004, 129, 1091.	3.5	7
33	Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: A phase 2 vaccine trial among US Army Infantry trainees. Vaccine, 2021, 39, 3179-3188.	3.8	6
34	Inactivation of NAD-dependent dehydrogenases from shallow- and deep-living fishes by hydrostatic pressure and proteolysis. BBA - Proteins and Proteomics, 1987, 913, 285-291.	2.1	5
35	Genetics, Biosynthesis, and Chemistry of Pneumococcal Capsular Polysaccharides. , 0, , 31-46.		4
36	Evaluation of the purity of a purified, inactivated hepatitis A vaccine (VAQTATM). Vaccine, 1999, 17, 2830-2835.	3.8	3

#	ARTICLE	IF	CITATIONS
37	A Robust Approach for the Quantitation of Viral Concentration in an Adenoviral Vector-Based Human Immunodeficiency Virus Vaccine by Real-Time Quantitative Polymerase Chain Reaction. Human Gene Therapy, 2006, .	2.7	0